JP2021078458A - Three-dimensional scaffold for cell culture, method for manufacturing the same, and cell dissemination method and cell culture method using the same - Google Patents
Three-dimensional scaffold for cell culture, method for manufacturing the same, and cell dissemination method and cell culture method using the same Download PDFInfo
- Publication number
- JP2021078458A JP2021078458A JP2019210643A JP2019210643A JP2021078458A JP 2021078458 A JP2021078458 A JP 2021078458A JP 2019210643 A JP2019210643 A JP 2019210643A JP 2019210643 A JP2019210643 A JP 2019210643A JP 2021078458 A JP2021078458 A JP 2021078458A
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- cell culture
- woven fabric
- cell
- dimensional scaffold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 111
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000003306 cell dissemination Effects 0.000 title 1
- 229920000159 gelatin Polymers 0.000 claims abstract description 185
- 108010010803 Gelatin Proteins 0.000 claims abstract description 182
- 239000008273 gelatin Substances 0.000 claims abstract description 182
- 235000019322 gelatine Nutrition 0.000 claims abstract description 182
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 182
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 108
- 239000000835 fiber Substances 0.000 claims abstract description 79
- 108010025899 gelatin film Proteins 0.000 claims abstract description 76
- 230000008961 swelling Effects 0.000 claims abstract description 29
- 239000007788 liquid Substances 0.000 claims description 35
- 239000012530 fluid Substances 0.000 claims description 30
- 238000010899 nucleation Methods 0.000 claims description 28
- 238000009987 spinning Methods 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000006285 cell suspension Substances 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 description 122
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 238000004132 cross linking Methods 0.000 description 26
- 239000002609 medium Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- -1 polyethylene terephthalate Polymers 0.000 description 7
- 238000003466 welding Methods 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 229920000249 biocompatible polymer Polymers 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000010894 electron beam technology Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Abstract
Description
本発明は、細胞播種効率が高く、細胞培養に適した細胞培養用立体足場、その製造方法、それを用いた細胞播種方法及び細胞培養方法に関する。 The present invention relates to a three-dimensional scaffold for cell culture, which has high cell seeding efficiency and is suitable for cell culture, a method for producing the same, a cell seeding method using the same, and a cell culture method.
繊維シートは、有孔度や比表面積の高さから、医療用及び細胞培養の足場等に有用である。特に生体適合性ポリマーを用いた繊維シートは、医療用及び細胞培養の足場として好適に用いられている。例えば、特許文献1には、ガーゼやスポンジ等の支持体上に、ゼラチン、コラーゲン及びセルロース等の生体高分子からなるナノファイバーを形成させて培養基材として用いることが記載されている。特許文献2には、平均繊維径が1〜70μmの生体適合性長繊維の繊維交点を部分的に溶着させた生体適合性長繊維不織布を細胞培養用足場として用いることが記載されている。
The fiber sheet is useful for medical use and as a scaffold for cell culture because of its high porosity and high specific surface area. In particular, fiber sheets using biocompatible polymers are suitably used as scaffolds for medical use and cell culture. For example, Patent Document 1 describes that nanofibers made of biopolymers such as gelatin, collagen and cellulose are formed on a support such as gauze or sponge and used as a culture medium.
しかし、特許文献1に記載の培養基材のように、ナノファイバーを用いた緻密な素材の場合、細胞が培養基材表面に留まりやすいという問題がある。また、特許文献2に記載の足場では、繊維径が大きすぎたり、不織布の目付が低いと疎な素材となり、細胞が足場内部を貫通して足場から脱落してしまう問題がある。
However, in the case of a dense material using nanofibers such as the culture medium described in Patent Document 1, there is a problem that cells tend to stay on the surface of the culture medium. Further, in the scaffold described in
本発明は、前記従来の問題を解決するため、細胞播種時に足場内部に細胞が侵入しやすく、かつ足場からの細胞の脱落を抑制することができる細胞培養用立体足場、その製造方法及びこれを用いた細胞培養方法を提供する。 In order to solve the above-mentioned conventional problems, the present invention provides a three-dimensional scaffold for cell culture, a method for producing the same, and a method for producing the same, which allows cells to easily invade the inside of the scaffold at the time of cell seeding and can suppress the detachment of cells from the scaffold. The cell culture method used is provided.
本発明は、ゼラチンを主成分とするゼラチン不織布及びゼラチンを主成分とするゼラチンフィルムを含む積層体で構成された細胞培養用立体足場において、前記ゼラチン不織布を構成するゼラチン繊維は、膨潤後の平均繊維径が2μm以上400μm以下であり、繊維交点が少なくとも部分的に溶着しており、前記ゼラチンフィルムは、前記ゼラチン不織布の一方の表面に積層され、前記ゼラチン不織布を構成するゼラチン繊維と部分的に溶着しており、前記ゼラチン不織布の厚みTnと前記ゼラチンフィルムの厚みTfの比Tf/Tnが7.5×10−3以下であることを特徴とする細胞培養用立体足場に関する。 In the present invention, in a three-dimensional scaffold for cell culture composed of a gelatin non-woven fabric containing gelatin as a main component and a laminate containing a gelatin film containing gelatin as a main component, the gelatin fibers constituting the gelatin non-woven fabric are averaged after swelling. The fiber diameter is 2 μm or more and 400 μm or less, the fiber intersections are at least partially welded, and the gelatin film is laminated on one surface of the gelatin non-woven fabric and partially with the gelatin fibers constituting the gelatin non-woven fabric. The present invention relates to a three-dimensional scaffold for cell culture, which is welded and has a ratio Tf / Tn of the thickness Tn of the gelatin non-woven fabric to the thickness Tf of the gelatin film of 7.5 × 10 -3 or less.
本発明は、また、前記細胞培養用立体足場の製造方法であって、ゼラチンを含む紡糸液をノズル吐出口から空気中に押し出し、前記ノズル吐出口の後方に位置し、前記ノズル吐出口とは非接触状態の流体噴射口から前方に向けて圧力流体を噴射し、前記押し出された紡糸液を前記圧力流体に随伴させて繊維形成させ、ゼラチンを主成分とするゼラチンフィルム上に前記繊維形成した繊維を集積させてゼラチン不織布とすることで、前記ゼラチンフィルムと前記ゼラチン不織布の積層体を得ることを特徴とする細胞培養用立体足場の製造方法に関する。 The present invention is also a method for producing a three-dimensional scaffold for cell culture, in which a spinning fluid containing gelatin is extruded into the air from a nozzle discharge port, and is located behind the nozzle discharge port. A pressure fluid was injected forward from a non-contact fluid injection port, and the extruded spinning liquid was accompanied by the pressure fluid to form fibers, and the fibers were formed on a gelatin film containing gelatin as a main component. The present invention relates to a method for producing a three-dimensional scaffold for cell culture, which comprises obtaining a laminate of the gelatin film and the gelatin non-woven fabric by accumulating fibers to form a gelatin non-woven fabric.
本発明は、また、前記の細胞培養用立体足場を用いた細胞培養方法であって、培養容器中に膨潤後の細胞培養用立体足場をゼラチンフィルムが培養容器の内底面に接するように配置する工程、及び細胞培養用立体足場のゼラチン不織布上に細胞懸濁液を滴下する工程を含むことを特徴とする細胞培養方法に関する。 The present invention is also a cell culture method using the above-mentioned three-dimensional cell culture scaffold, in which the three-dimensional scaffold for cell culture after swelling is arranged in the culture vessel so that the gelatin film is in contact with the inner bottom surface of the culture vessel. The present invention relates to a cell culture method comprising a step and a step of dropping a cell suspension onto a gelatin non-woven fabric of a three-dimensional scaffold for cell culture.
本発明は、また、前記の細胞播種方法において、細胞培養用立体足場のゼラチン不織布上に細胞懸濁液を滴下して所定時間静置した後、液体培地を添加して細胞培養を行う細胞培養方法に関する。 Further, in the above-mentioned cell seeding method, the present invention is a cell culture in which a cell suspension is dropped onto a gelatin non-woven fabric of a three-dimensional scaffold for cell culture, allowed to stand for a predetermined time, and then a liquid medium is added to perform cell culture. Regarding the method.
本発明は、細胞播種時に、足場内部に細胞が侵入しやすく、かつ足場からの細胞の脱落を抑制することができる細胞培養用立体足場を提供することができる。
また、本発明の製造方法によれば、バインダー成分や熱圧着手段を用いることなく、ゼラチン不織布とゼラチンフィルムが一体化された積層体で構成された細胞培養用立体足場を得ることができる。
また、本発明の細胞播種方法によれば、足場内部に細胞が侵入しやすく、かつ足場からの細胞の脱落を抑制することができる。
また、本発明の細胞培養方法によれば、細胞の3次元培養を行うことができる。
The present invention can provide a three-dimensional scaffold for cell culture in which cells can easily invade the inside of the scaffold at the time of cell seeding and can suppress the shedding of cells from the scaffold.
Further, according to the production method of the present invention, it is possible to obtain a three-dimensional scaffold for cell culture composed of a laminate in which a gelatin non-woven fabric and a gelatin film are integrated without using a binder component or thermocompression bonding means.
In addition, according to the cell seeding method of the present invention, cells can easily invade the inside of the scaffold and the shedding of cells from the scaffold can be suppressed.
Further, according to the cell culture method of the present invention, three-dimensional culture of cells can be performed.
本発明の発明者らは、上述した問題を解決するため、検討を重ねた。その結果、細胞培養用立体足場を、ゼラチンを主成分とするゼラチン不織布と、ゼラチンを主成分とするゼラチンフィルムを含む積層体で構成し、前記ゼラチン不織布を構成するゼラチン繊維の平均繊維径を2μm以上400μm以下とし、繊維交点を少なくとも部分的に溶着させ、前記ゼラチン不織布の一方の表面に前記ゼラチンフィルムを積層して前記ゼラチン不織布を構成するゼラチン繊維と部分的に溶着させるとともに、前記ゼラチン不織布の厚みTnと前記ゼラチンフィルムの厚みTfの比Tf/Tnを7.5×10−3以下にすることで、細胞播種時に、足場内部に細胞が侵入しやすく、かつ足場からの細胞の脱落を抑制することができる細胞培養用立体足場を提供する。本発明において、「膨潤」とは、水、緩衝液又は液体培地で飽和状態まで膨潤することを意味する。 The inventors of the present invention have repeated studies in order to solve the above-mentioned problems. As a result, the three-dimensional scaffold for cell culture is composed of a laminate containing a gelatin non-woven fabric containing gelatin as a main component and a gelatin film containing gelatin as a main component, and the average fiber diameter of the gelatin fibers constituting the gelatin non-woven fabric is 2 μm. The thickness is 400 μm or less, the fiber intersections are at least partially welded, the gelatin film is laminated on one surface of the gelatin non-woven fabric, and the gelatin fibers constituting the gelatin non-woven fabric are partially welded, and the gelatin non-woven fabric is partially welded. By setting the ratio Tf / Tn of the thickness Tn to the thickness Tf of the gelatin film to 7.5 × 10 -3 or less, cells can easily invade the inside of the scaffold at the time of cell seeding and the detachment of the cells from the scaffold is suppressed. Provide a three-dimensional scaffold for cell culture that can be used. In the present invention, "swelling" means swelling to saturation with water, buffer or liquid medium.
前記ゼラチン不織布において、ゼラチン繊維の膨潤後の平均繊維径が2μm以上400μm以下であり、繊維交点が部分的に溶着していることにより、ゼラチン不織布は嵩高いブリッジ構造となり、細胞播種時に細胞が足場に侵入しやすい。また、水を含んだ場合でも不織布の力学強度が劣らず、細胞培養時における不織布の変形の抑制、内部構造(空隙)の維持、細胞親和性の高いゼラチン繊維を用いることで、細胞の生理学的環境が整えられたことで、細胞培養時に不織布内側及び外側で細胞が増殖でき、細胞の3次元組織化が可能になると考えられる。 In the gelatin non-woven fabric, the average fiber diameter after swelling of the gelatin fibers is 2 μm or more and 400 μm or less, and the fiber intersections are partially welded, so that the gelatin non-woven fabric has a bulky bridge structure, and the cells are scaffolded at the time of cell seeding. Easy to invade. In addition, the mechanical strength of the non-woven fabric is not inferior even when it contains water, and by suppressing the deformation of the non-woven fabric during cell culture, maintaining the internal structure (voids), and using gelatin fibers with high cell affinity, the physiology of the cells It is considered that when the environment is prepared, cells can proliferate inside and outside the non-woven fabric during cell culture, and three-dimensional organization of cells becomes possible.
前記ゼラチン不織布を構成するゼラチン繊維とゼラチンフィルムが部分的に溶着することで、ゼラチン不織布とゼラチンフィルムが一体化されていることで、細胞が足場を貫通して細胞から脱落することが抑制される。また前記ゼラチン不織布の厚みTnと前記ゼラチンフィルムの厚みTfの比Tf/Tnが7.5×10−3以下である、すなわちゼラチンフィルムが適切な厚みを有することで、膨潤後における積層体の反りが抑制され、細胞懸濁液が積層体の側面に流出しにくくなり、それゆえ、足場からの細胞の脱落が抑制される。さらに、細胞培養時に積層体が膨潤した場合でも、ゼラチン不織布にゼラチンフィルムが追従しやすく、ゼラチンフィルムの剥離や破壊が生じにくい。 By partially welding the gelatin fibers constituting the gelatin non-woven fabric and the gelatin film, the gelatin non-woven fabric and the gelatin film are integrated, so that the cells are prevented from penetrating the scaffold and falling out from the cells. .. Further, the ratio Tf / Tn of the thickness Tn of the gelatin non-woven fabric to the thickness Tf of the gelatin film is 7.5 × 10 -3 or less, that is, the gelatin film has an appropriate thickness, so that the laminate is warped after swelling. Is suppressed and the cell suspension is less likely to flow out to the sides of the laminate, thus suppressing the shedding of cells from the scaffold. Furthermore, even when the laminate swells during cell culture, the gelatin film easily follows the gelatin non-woven fabric, and the gelatin film is less likely to peel off or break.
前記ゼラチン不織布及びゼラチンフィルムは、いずれも、ゼラチンを主成分とする。本発明において、主成分とは、ゼラチンを90質量%以上含むことを意味する。10質量%以下の他の成分は、必要に応じて、他の生体適合性ポリマー、架橋剤、薬剤、可塑剤、他の添加剤等であってもよい。実質的に100質量%のゼラチンであってもよい。本発明の細胞培養用立体足場は、安全性が高く、生体吸収性に優れるゼラチンを主成分とすることから、該足場は、生体に移植して再生治療用、細胞研究及び創薬研究に必要となる三次元培養組織体等として好適に用いることができる。 Both the gelatin non-woven fabric and the gelatin film contain gelatin as a main component. In the present invention, the main component means that gelatin is contained in an amount of 90% by mass or more. Other components of 10% by mass or less may be other biocompatible polymers, cross-linking agents, chemicals, plasticizers, other additives and the like, if necessary. It may be substantially 100% by mass gelatin. Since the three-dimensional scaffold for cell culture of the present invention contains gelatin as a main component, which is highly safe and has excellent bioabsorbability, the scaffold is necessary for regenerative therapy, cell research and drug discovery research by transplanting into a living body. It can be suitably used as a three-dimensional cultured tissue or the like.
前記ゼラチンの原材料となるコラーゲンが由来する動物の種類や部位は特に限定されない。コラーゲンは、例えば脊髄動物由来でもよく、魚由来でもよい。また、真皮、靭帯、腱、骨、軟骨等の様々な器官や組織由来のコラーゲンを適宜用いることができる。また、コラーゲンからゼラチンを調製する方法も特に限定されず、例えば酸処理、アルカリ処理、及び酵素処理等が挙げられる。前記ゼラチンの分子量も特に限定されず、様々な分子量のものを適宜選択して用いることができる。また、ゼラチンは、1種を用いてもよく、2種以上を併用してもよい。 The type and site of the animal from which collagen, which is the raw material of gelatin, is derived are not particularly limited. Collagen may be derived from, for example, vertebrates or fish. In addition, collagen derived from various organs and tissues such as dermis, ligaments, tendons, bones and cartilage can be appropriately used. Further, the method for preparing gelatin from collagen is not particularly limited, and examples thereof include acid treatment, alkali treatment, and enzyme treatment. The molecular weight of the gelatin is also not particularly limited, and those having various molecular weights can be appropriately selected and used. In addition, one type of gelatin may be used, or two or more types may be used in combination.
前記ゼラチンは、特に限定されないが、適度な柔軟性及び硬さを有し、足場のハンドリング性を高める観点から、ゼリー強度が100g以上400g以下であることが好ましく、より好ましくは150g以上360g以下である。本発明において、ゼリー強度は、JIS K 6503に準じて測定する。前記ゼラチンは、市販品であってもよい。 The gelatin is not particularly limited, but has appropriate flexibility and hardness, and from the viewpoint of enhancing the handleability of the scaffold, the jelly strength is preferably 100 g or more and 400 g or less, and more preferably 150 g or more and 360 g or less. is there. In the present invention, the jelly strength is measured according to JIS K 6503. The gelatin may be a commercially available product.
前記他の生体適合性ポリマーとしては、特に限定されないが、例えば、天然高分子や合成高分子を用いることができる。天然高分子としては、例えばタンパク質や多糖類が挙げられる。タンパク質としては、例えばコラーゲン、フィブロネクチン、フィブリノーゲン、ラミニン、フィブリン等が挙げられる。多糖類としては、例えばキトサン、アルギン酸カルシウム、ヘパラン硫酸、コンドロイチン硫酸、ヒアルロン酸、ヘパリン、 デンプン、ジェランガム、アガロース、グァーガム、キサンタンガム、カラギーナン、ペクチン、ローカストビーンガム、タマリンドガム、ダイユータンガム等の天然高分子を用いてもよく、カルボキシメチルセルロース等の天然高分子の誘導体を用いてもよい。合成高分子としては、例えば、ポリエチレングリコールポロエチレングリコール、ポリエチレンテレフタレート、ポリビニルアルコール、熱可塑性エラストマー、ポリプロピレン、ポリエチレン、ポリスチレン、ポリメタクリル酸メチル、ポリカーボネート、ポリジメチルシロキサン、シクロオレフィンポリマー、アモルファスフッ素樹脂等の非吸収性の合成高分子や、ポリ乳酸、ポリグルコール酸、ポリカプロラクトン、ポリジオキサノン等の生体吸収性高分子等が挙げられる。上述した他の生体適合ポリマーは、1種を用いてもよく、2種以上を用いてもよい。 The other biocompatible polymer is not particularly limited, and for example, a natural polymer or a synthetic polymer can be used. Examples of natural polymers include proteins and polysaccharides. Examples of the protein include collagen, fibronectin, fibrinogen, laminin, fibrin and the like. Examples of polysaccharides include chitosan, calcium alginate, heparan sulfate, chondroitin sulfate, hyaluronic acid, heparin, starch, gellan gum, agarose, guar gum, xanthan gum, carrageenan, pectin, locust bean gum, tamarind gum, and dietangum. A molecule may be used, or a derivative of a natural polymer such as carboxymethyl cellulose may be used. Examples of the synthetic polymer include polyethylene glycol polyethylene glycol, polyethylene terephthalate, polyvinyl alcohol, thermoplastic elastomer, polypropylene, polyethylene, polystyrene, polymethylmethacrylate, polycarbonate, polydimethylsiloxane, cycloolefin polymer, and amorphous fluororesin. Examples thereof include non-absorbable synthetic polymers and bioabsorbable polymers such as polylactic acid, polyglucoric acid, polycaprolactone and polydioxanone. As the other biocompatible polymers described above, one type may be used, or two or more types may be used.
前記ゼラチン不織布を構成するゼラチン繊維は、膨潤後の平均繊維径が2μm以上400μm以下であり、好ましくは5μm以上300μm以下であり、より好ましくは10μm以上200μm以下であり、さらに好ましくは15μm以上100μm以下である。ゼラチン繊維の平均繊維径が上記範囲内であると、細胞培養用立体足場のゼラチン不織布の表面上に細胞を播種した際、細胞が細胞培養用立体足場に侵入しやすい上、細胞培養用立体足場の内部に均一に分布しやすい。本発明において、「膨潤後の平均繊維径」は、膨潤後の細胞培養用立体足場におけるゼラチン不織布から任意に選択した50本の繊維の直径の平均値を意味する。 The gelatin fibers constituting the gelatin non-woven fabric have an average fiber diameter of 2 μm or more and 400 μm or less, preferably 5 μm or more and 300 μm or less, more preferably 10 μm or more and 200 μm or less, and further preferably 15 μm or more and 100 μm or less. Is. When the average fiber diameter of the gelatin fibers is within the above range, when the cells are seeded on the surface of the gelatin non-woven fabric of the three-dimensional scaffold for cell culture, the cells easily invade the three-dimensional scaffold for cell culture and the three-dimensional scaffold for cell culture. It is easy to distribute evenly inside the cell. In the present invention, the "average fiber diameter after swelling" means the average value of the diameters of 50 fibers arbitrarily selected from the gelatin non-woven fabric in the three-dimensional scaffold for cell culture after swelling.
前記ゼラチン不織布を構成するゼラチン繊維は、繊維交点が部分的に溶着している。この部分的溶着は、後述するように、細胞培養用立体足場の製造時に圧力流体によって吹き飛ばされたゼラチン繊維が堆積する際に、完全に固化していない状態の時に発現する。この部分的溶着により、ゼラチン不織布はブリッジ構造となり、嵩高く低密度であり、所望の形に成形しやすく、かつ成形安定性も高いものとなる。本発明において、繊維交点が部分的に溶着していることにより、ゼラチン不織布は水に濡れてもへたらない。また、ゼラチン不織布において、繊維交点は一部が溶着してもよく、繊維交点の全部が溶着してもよい。 The gelatin fibers constituting the gelatin non-woven fabric have fiber intersections partially welded. As will be described later, this partial welding occurs when gelatin fibers blown off by a pressure fluid are deposited during the production of a three-dimensional scaffold for cell culture and are not completely solidified. By this partial welding, the gelatin non-woven fabric has a bridge structure, is bulky and has a low density, is easy to be molded into a desired shape, and has high molding stability. In the present invention, since the fiber intersections are partially welded, the gelatin non-woven fabric does not become flat even when wet with water. Further, in the gelatin non-woven fabric, some of the fiber intersections may be welded, or all of the fiber intersections may be welded.
前記ゼラチン不織布は、特に限定されないが、例えば、ハンドリング性及び細胞の侵入性を高める観点から、厚みが0.1mm以上であることが好ましく、0.2mm以上であることがより好ましく、0.3mm以上であることがさらに好ましく、0.4mm以上であることが特に好ましい。また、前記ゼラチン不織布は、特に限定されないが、例えば、3次元培養における細胞の生存率を高める観点から、厚みが2mm以下であることが好ましく、1.5mm以下であることがより好ましく、1mm以下であることがさらに好ましく、0.7mm以下であることが特に好ましい。 The gelatin non-woven fabric is not particularly limited, but for example, from the viewpoint of enhancing handleability and cell invasion, the thickness is preferably 0.1 mm or more, more preferably 0.2 mm or more, and more preferably 0.3 mm. The above is more preferable, and 0.4 mm or more is particularly preferable. The gelatin non-woven fabric is not particularly limited, but for example, from the viewpoint of increasing the viability of cells in three-dimensional culture, the thickness is preferably 2 mm or less, more preferably 1.5 mm or less, and 1 mm or less. Is more preferable, and 0.7 mm or less is particularly preferable.
前記ゼラチン不織布は、特に限定されないが、例えば、細胞の脱落を抑制する観点から、目付が10g/m2以上であることが好ましく、25g/m2以上であることがより好ましく、50g/m2以上であることがさらに好ましく、100g/m2以上であることが特に好ましい。また、前記ゼラチン不織布は、特に限定されないが、例えば、細胞の侵入性及び3次元培養における細胞の生存率を高める観点から、目付が600g/m2以下であることが好ましく、500g/m2以下であることがより好ましく、400g/m2以下であることがさらに好ましい。 The gelatin nonwoven fabric is not particularly limited, for example, from the viewpoint of suppressing detachment of cells, it is preferable that the basis weight is 10 g / m 2 or more, more preferably 25 g / m 2 or more, 50 g / m 2 The above is more preferable, and 100 g / m 2 or more is particularly preferable. The gelatin non-woven fabric is not particularly limited, but for example, from the viewpoint of enhancing cell invasion and cell viability in 3D culture, the basis weight is preferably 600 g / m 2 or less, and 500 g / m 2 or less. Is more preferable, and 400 g / m 2 or less is further preferable.
前記ゼラチン不織布は、特に限定されないが、例えば、細胞の侵入性及び3次元培養における細胞の生存率を高める観点から、細孔径が20μm以上であることが好ましく、30μm以上であることがより好ましく、40μm以上であることがさらに好ましい。また、前記ゼラチン不織布は、特に限定されないが、例えば、細胞の脱落を抑制する観点から、細孔径が400μm以下であることが好ましく、300μm以下であることがより好ましく、200μm以下であることがさらに好ましい。本発明において、ゼラチン不織布の細孔径は、Wrotnowskiの仮定に基づいて、下記計算式(1)にて算出することができる。
前記ゼラチンフィルムは、前記ゼラチン不織布の一方の表面に配置されており、前記ゼラチン不織布を構成するゼラチン繊維と部分的に溶着している。この部分的溶着は、後述するように、細胞培養用立体足場の製造時に圧力流体によって吹き飛ばされたゼラチン繊維がゼラチンフィルム上に堆積する際に、完全に固化していない状態の時に発現する。この部分的溶着により、ゼラチン不織布とゼラチンフィルムが一体化されており、細胞が足場を貫通して細胞から脱落することが抑制される。 The gelatin film is arranged on one surface of the gelatin nonwoven fabric and is partially welded to the gelatin fibers constituting the gelatin nonwoven fabric. This partial welding occurs when the gelatin fibers blown off by the pressure fluid during the production of the cell culture scaffold are not completely solidified when they are deposited on the gelatin film, as will be described later. By this partial welding, the gelatin non-woven fabric and the gelatin film are integrated, and the cells are prevented from penetrating the scaffold and falling out from the cells.
前記ゼラチン不織布の厚みTnと前記ゼラチンフィルムの厚みTfの比Tf/Tnが7.5×10−3以下である。これにより、膨潤後における積層体の反りが抑制され、細胞懸濁液が積層体の側面に流出しにくくなり、それゆえ、足場からの細胞の脱落が抑制される。さらに、積層体が膨潤した場合でも、ゼラチン不織布にゼラチンフィルムが追従しやすく、ゼラチンフィルムの剥離や破壊が生じにくい。前記Tf/Tnは、7.0×10−3以下であることが好ましく、6.0×10−3以下であることがより好ましい。また、前記Tf/Tnは、ゼラチンフィルムの剥離や破壊を抑制しやすい観点から、1.0×10−3以上であることが好ましく、1.5×10−3以上であることがより好ましい。 The ratio Tf / Tn of the thickness Tn of the gelatin non-woven fabric to the thickness Tf of the gelatin film is 7.5 × 10 -3 or less. As a result, the warp of the laminate after swelling is suppressed, the cell suspension is less likely to flow out to the side surface of the laminate, and therefore the shedding of cells from the scaffold is suppressed. Further, even when the laminate is swollen, the gelatin film easily follows the gelatin non-woven fabric, and the gelatin film is less likely to be peeled off or broken. The Tf / Tn is preferably 7.0 × 10 -3 or less, and more preferably 6.0 × 10 -3 or less. Further, the Tf / Tn is preferably 1.0 × 10 -3 or more, and more preferably 1.5 × 10 -3 or more, from the viewpoint of easily suppressing peeling or breakage of the gelatin film.
前記ゼラチンフィルムは、一例として、簡便性及びハンドリング性の観点から、厚みが0.5μm以上であることが好ましく、0.6μm以上であることがより好ましく、0.7μm以上であることがさらに好ましく、0.8μm以上であることが特に好ましい。また、前記ゼラチンフィルムは、一例として、ゼラチン不織布との一体性及び細胞の3次元培養の効率を高める観点から、厚みが10μm以下であることが好ましく、8μm以下であることがより好ましく、6μm以下であることがさらに好ましく、4μm以下であることが特に好ましい。 As an example, from the viewpoint of convenience and handleability, the gelatin film preferably has a thickness of 0.5 μm or more, more preferably 0.6 μm or more, and further preferably 0.7 μm or more. , 0.8 μm or more is particularly preferable. Further, as an example, the gelatin film preferably has a thickness of 10 μm or less, more preferably 8 μm or less, and 6 μm or less, from the viewpoint of enhancing the integrity with the gelatin non-woven fabric and the efficiency of three-dimensional culture of cells. It is more preferably 4 μm or less.
前記ゼラチンフィルムは、無孔フィルムであることが好ましいが、細胞が貫通しないぐらいの大きさ、例えば細孔径が10μm以下又は5μm以下程度の微小孔を有してもよい。 The gelatin film is preferably a non-porous film, but may have micropores having a size such that cells do not penetrate, for example, a pore diameter of about 10 μm or less or about 5 μm or less.
前記積層体は、特に限定されないが、例えば、細胞培養時に強度を保ち、3次元培養における細胞の生存率を高める観点から、水で飽和状態まで膨潤した後における1.0kPaの圧縮応力時の圧縮変形率(以下において、単に「圧縮変形率」とも記す。)が40%以下であることが好ましく、35%以下であることがより好ましく、30%以下がさらに好ましい。前記飽和状態とは、水が最大限に含まれた状態であり、水の含有量が一定限度にとどまりそれ以上増えない状態を意味する。本明細書において、圧縮変形率は、水で飽和状態まで膨潤した後の積層体において、無荷重の時の厚さを(H1)とし、1.0kPaの圧縮応力時の厚さを(H2)とした場合、下記式で算出したものである。圧縮試験は、後述のとおりに行う。
圧縮変形率(%)=100−{(H2/H1)×100}
The laminate is not particularly limited, but for example, from the viewpoint of maintaining strength during cell culture and increasing cell viability in three-dimensional culture, compression under compressive stress of 1.0 kPa after swelling to a saturated state with water. The deformation rate (hereinafter, also simply referred to as “compression deformation rate”) is preferably 40% or less, more preferably 35% or less, still more preferably 30% or less. The saturated state means a state in which water is contained to a maximum, and a state in which the water content stays at a certain limit and does not increase any more. In the present specification, the compressive deformation rate is defined as (H1) the thickness under no load and (H2) the thickness under compressive stress of 1.0 kPa in the laminated body after being swollen to a saturated state with water. If, it is calculated by the following formula. The compression test is performed as described below.
Compression deformation rate (%) = 100-{(H2 / H1) x 100}
前記ゼラチン不織布及び前記ゼラチンフィルムは、耐水性を高め、細胞培養時の形態を維持しやすく、効果的に細胞の3次元培養を行う観点から、架橋されていることが好ましい。架橋は、架橋剤等の化合物を用いた化学架橋であってもよいが、生体安全性の観点から、生体安全性を有する架橋剤を用いる架橋、又は架橋剤を用いない架橋であることが好ましい。架橋剤を用いない架橋としては、例えば、熱架橋、電子線架橋、γ線等の放射線架橋、紫外線架橋等が挙げられ、簡便に所望の架橋効果を得やすい観点から、熱架橋であることが好ましく、熱脱水架橋であることがより好ましい。 The gelatin non-woven fabric and the gelatin film are preferably crosslinked from the viewpoint of increasing water resistance, easily maintaining the morphology during cell culture, and effectively performing three-dimensional culture of cells. The cross-linking may be a chemical cross-linking using a compound such as a cross-linking agent, but from the viewpoint of biosafety, a cross-linking using a cross-linking agent having biosafety or a cross-linking without using a cross-linking agent is preferable. .. Examples of the cross-linking without using a cross-linking agent include thermal cross-linking, electron beam cross-linking, radiation cross-linking such as γ-ray, ultraviolet cross-linking, and the like. Preferably, it is a thermal dehydration crosslink.
本発明の1以上の実施形態において、前記ゼラチン不織布とゼラチンフィルムの積層体は、細胞接着因子、細胞誘導因子、細胞増殖因子、細胞に栄養やエネルギーを与える物質、細胞の機能を抑制または亢進する物質等でコーティングされてもよい。細胞接着因子としては、特に限定されないが、例えば、フィブロネクチン等が挙げられる。細胞に栄養やエネルギーを与える物質としては、特に限定されないが、例えば、ATP、ピルビン酸、グルタミン等が挙げられる。また、本発明の1以上の実施形態において、前記ゼラチン不織布とゼラチンフィルムの積層体を細胞誘導因子、細胞増殖因子等の生理活性物質を含む溶液に浸して、これらの成分を含ませてもよい。細胞培養過程において、積層体から、これらの生理活性物質が徐々に放出されることで、細胞培養を促進することができる。 In one or more embodiments of the present invention, the laminate of gelatin non-woven fabric and gelatin film suppresses or enhances cell adhesion factors, cell inducing factors, cell growth factors, substances that nourish or energize cells, and cell functions. It may be coated with a substance or the like. The cell adhesion factor is not particularly limited, and examples thereof include fibronectin and the like. The substance that gives nutrients and energy to cells is not particularly limited, and examples thereof include ATP, pyruvic acid, and glutamine. Further, in one or more embodiments of the present invention, the laminate of the gelatin non-woven fabric and the gelatin film may be immersed in a solution containing a physiologically active substance such as a cell-inducing factor and a cell growth factor to contain these components. .. In the cell culture process, these physiologically active substances are gradually released from the laminate, so that cell culture can be promoted.
本発明の1以上の実施形態において、細胞培養用立体足場は、特に限定されないが、夾雑物の発生を抑制し、製品汚染を防ぐとともに、バインダー成分や熱圧着手段を用いることなく、ゼラチン不織布とゼラチンフィルムを一体化する観点から、ゼラチンを含む紡糸液をノズル吐出口から空気中に押し出し、前記ノズル吐出口の後方に位置し、前記ノズル吐出口とは非接触状態の流体噴射口から前方に向けて圧力流体を噴射し、前記押し出された紡糸液を前記圧力流体に随伴させて繊維形成させ、ゼラチンを主成分とするゼラチンフィルム上に前記繊維形成した繊維を集積させてゼラチン不織布とすることで、前記ゼラチンフィルムと前記ゼラチン不織布の積層体を得ることで作製することが好ましい。 In one or more embodiments of the present invention, the three-dimensional scaffold for cell culture is not particularly limited, but it suppresses the generation of contaminants, prevents product contamination, and uses a gelatin non-woven fabric without using a binder component or heat-bonding means. From the viewpoint of integrating the gelatin film, the spinning liquid containing gelatin is extruded into the air from the nozzle discharge port, located behind the nozzle discharge port, and forward from the fluid injection port in a non-contact state with the nozzle discharge port. A pressure fluid is jetted toward the surface, the extruded spinning liquid is associated with the pressure fluid to form fibers, and the fiber-formed fibers are accumulated on a gelatin film containing gelatin as a main component to form a gelatin non-woven fabric. Therefore, it is preferable to obtain a laminate of the gelatin film and the gelatin non-woven fabric.
前記ゼラチンフィルムは、特に限定されず、公知のフィルムの製造方法で作製することができる。例えば、ゼラチン溶液を基材表面に塗布した後、乾燥することで作製することができる。前記基材としては、例えば、ポリエチレンテレフタレートフィルム(PETフィルム)、ガラス板、ポリスチレンシート、フッ素樹脂シート等を用いることができる。PETフィルム、ガラス板、ポリスチレンシート、フッ素樹脂シート等は撥水処理されてもよい。 The gelatin film is not particularly limited, and can be produced by a known method for producing a film. For example, it can be produced by applying a gelatin solution to the surface of a substrate and then drying it. As the base material, for example, a polyethylene terephthalate film (PET film), a glass plate, a polystyrene sheet, a fluororesin sheet, or the like can be used. The PET film, glass plate, polystyrene sheet, fluororesin sheet and the like may be treated with water repellency.
前記ゼラチン溶液は、ゼラチン単独、或いは、必要に応じてゼラチンと上述した他の成分として用いることができる他の生体適合ポリマーを溶媒に溶解することで得ることができる。溶媒としては、例えば、水、エタノール、1−プロパノール、2−プロパノール、グリセリン等のアルコール類、あるいはジメチルホルムアミド、ジメチルアセトアミド等のアミド類等が挙げられる。これらの溶媒は、1種を単独で用いてもよく、2種以上を混合して用いてもよい。中でも、取扱い性の観点から、蒸留水、純水、超純水、イオン交換水等の水を用いることが好ましい。ゼラチンが水溶性であることで、水溶液の状態でフィルム化に用いることができ、生体に対する安全性が高くなる。 The gelatin solution can be obtained by dissolving gelatin alone or, if necessary, gelatin and other biocompatible polymers that can be used as the above-mentioned other components in a solvent. Examples of the solvent include water, ethanol, alcohols such as 1-propanol, 2-propanol and glycerin, and amides such as dimethylformamide and dimethylacetamide. One of these solvents may be used alone, or two or more of these solvents may be mixed and used. Above all, from the viewpoint of handleability, it is preferable to use water such as distilled water, pure water, ultrapure water, and ion-exchanged water. Since gelatin is water-soluble, it can be used for film formation in the state of an aqueous solution, and the safety to the living body is enhanced.
ゼラチンの濃度は、特に限定されないが、例えば、成膜性及び流延性の観点から、ゼラチン溶液を100質量%とした時、0.1質量%以上35質量%以下であることが好ましく、1質量%以上30質量%以下であることがより好ましく、3質量%以上20質量%以下であることがさらに好ましい。溶解温度(溶媒の温度)は10℃以上90℃以下が好ましく、20℃以上80℃以下であることがより好ましく、30℃以上70℃以下であることがさらに好ましい。必要に応じて、ゼラチンを溶媒に溶解した後、フィルトレーションして異物やごみ等を除去してもよい。また、必要に応じて、その後、減圧又は真空脱泡して溶解空気を除去してもよい。効率よく気体(気泡)を除去する観点から、減圧脱泡時の真空度は5kPa以上30kPa以下であることが好ましい。 The concentration of gelatin is not particularly limited, but for example, from the viewpoint of film forming property and ductility, when the gelatin solution is 100% by mass, it is preferably 0.1% by mass or more and 35% by mass or less, and 1% by mass. It is more preferably% or more and 30% by mass or less, and further preferably 3% by mass or more and 20% by mass or less. The dissolution temperature (solvent temperature) is preferably 10 ° C. or higher and 90 ° C. or lower, more preferably 20 ° C. or higher and 80 ° C. or lower, and further preferably 30 ° C. or higher and 70 ° C. or lower. If necessary, gelatin may be dissolved in a solvent and then filtered to remove foreign substances, dust and the like. Further, if necessary, the dissolved air may be removed by depressurizing or vacuum defoaming thereafter. From the viewpoint of efficiently removing gas (air bubbles), the degree of vacuum at the time of defoaming under reduced pressure is preferably 5 kPa or more and 30 kPa or less.
前記乾燥は特に限定されず、例えば、自然乾燥、加熱乾燥、減圧乾燥(真空乾燥)、強制排気乾燥、強制循環対流等により行うことができる。具体的に、乾燥温度は、例えば、−40℃以上90℃以下であってもよく、0℃以上60℃以下であってもよく、10℃以上40℃以下であってもよい。また、乾燥時間は、例えば、1〜200時間の範囲であってもよく、好ましくは3〜100時間の範囲であり、より好ましくは5〜48時間の範囲である。 The drying is not particularly limited, and can be performed by, for example, natural drying, heat drying, vacuum drying (vacuum drying), forced exhaust drying, forced circulation convection, or the like. Specifically, the drying temperature may be, for example, −40 ° C. or higher and 90 ° C. or lower, 0 ° C. or higher and 60 ° C. or lower, or 10 ° C. or higher and 40 ° C. or lower. The drying time may be, for example, in the range of 1 to 200 hours, preferably in the range of 3 to 100 hours, and more preferably in the range of 5 to 48 hours.
本発明で用いるメルトブロー法は、ゼラチンを含む紡糸液をノズル吐出口から押し出し、ノズル吐出口の後方に位置し、前記ノズル吐出口とは非接触状態の流体噴射口から前方に向けて圧力流体を噴射し、前記押し出された紡糸液を前記圧力流体に随伴させて乾式でダイレクトに繊維化し、得られたゼラチン繊維をゼラチンフィルム上に集積させて不織布にすることから、コンタミ(夾雑物)の発生は防止され、衛生的に製造できる。紡糸後に繊維を集積(堆積)させる時に繊維同士が、水分を含んだ状態で積層されるため、繊維同士が溶着したり互いに絡んで一体化されるとともに、該不織布を構成するゼラチン繊維がゼラチンフィルムと溶着してゼラチン不織布とゼラチンフィルムが一体化する。繊維を堆積させる際の捕集距離を変えることで、容易に不織布密度を変えることができる。 In the melt blow method used in the present invention, the spinning liquid containing gelatin is extruded from the nozzle discharge port, and the pressure fluid is directed forward from the fluid injection port which is located behind the nozzle discharge port and is not in contact with the nozzle discharge port. The extruded spinning liquid is sprayed and accompanied by the pressure fluid to be directly fiberized by a dry method, and the obtained gelatin fibers are accumulated on a gelatin film to form a non-woven fabric, so that contamination (contamination) is generated. Is prevented and can be manufactured hygienically. When the fibers are accumulated (deposited) after spinning, the fibers are laminated in a state of containing water, so that the fibers are welded or entangled with each other and integrated, and the gelatin fibers constituting the non-woven fabric are gelatin films. The gelatin non-woven fabric and the gelatin film are integrated by welding. The density of the non-woven fabric can be easily changed by changing the collection distance when the fibers are deposited.
図10は本発明の一実施例で使用する細胞培養用立体足場の製造装置の模式的説明図である。細胞培養用立体足場の製造装置20において、加温槽1に入れたゼラチンを含む紡糸液2をノズル吐出口3から空気中に押し出す。加温槽1にはコンプレッサー4により、所定の圧力をかけておく。12は保温容器である。
また、ノズル吐出口3の後方に位置し、ノズル吐出口3とは非接触状態の流体噴射口5から前方に向けて圧力流体7を噴射させる。流体噴射口5にはコンプレッサー6から圧力流体(例えば圧空)が供給される。流体噴射口5とノズル吐出口3との距離は5〜30mmが好ましい。
押し出された紡糸液は圧力流体7に随伴されてゼラチン繊維8となり、巻き取りロール11上に配置されたゼラチンフィルム10上でゼラチン不織布9となって堆積される。この時、堆積された繊維は水分を含んでいたり、完全には固化していないので、繊維交点の少なくとも一部において接している繊維が互いに溶着するとともに、不織布を構成するゼラチン繊維がゼラチンフィルムと溶着してゼラチン不織布とゼラチンフィルムが一体化する。なお、巻き取りロールに変えてネット等の他の捕集手段を用いてもよい。
FIG. 10 is a schematic explanatory view of an apparatus for manufacturing a three-dimensional scaffold for cell culture used in one embodiment of the present invention. In the cell culture three-dimensional
Further, the pressure fluid 7 is injected forward from the
The extruded spinning liquid is accompanied by the pressure fluid 7 to become gelatin fibers 8, and is deposited as gelatin non-woven fabric 9 on the
まず、ゼラチン単独、或いは、必要に応じてゼラチンと上述した他の成分として用いることができる他の生体適合ポリマーを溶媒、好ましくは水に溶解して紡糸液を調製する。溶解温度(水等の溶媒の温度)は20℃以上90℃以下が好ましく、40℃以上90℃以下であることがより好ましい。必要に応じて、ゼラチンを水等の溶媒に溶解した後、フィルトレーションして異物やごみ等を除去してもよい。また、必要に応じて、その後、減圧又は真空脱泡して溶解空気を除去してもよい。効率よく気体(気泡)を除去する観点から、減圧脱泡時の真空度は5kPa以上30kPa以下であることが好ましい。ゼラチンが水溶性であることで、紡糸液として水溶液の状態で紡糸でき、生体に対する安全性が高くなる。水としては、例えば、純水、蒸留水、超純水等を適宜用いることができる。なお、他の成分として、他の生体適合性水溶性高分子を用いる場合、ゼラチンと同時に水に溶解することで、紡糸液を調製することができる。 First, gelatin alone or, if necessary, gelatin and other biocompatible polymers that can be used as the above-mentioned other components are dissolved in a solvent, preferably water, to prepare a spinning solution. The dissolution temperature (temperature of a solvent such as water) is preferably 20 ° C. or higher and 90 ° C. or lower, and more preferably 40 ° C. or higher and 90 ° C. or lower. If necessary, gelatin may be dissolved in a solvent such as water and then filtered to remove foreign substances and dust. Further, if necessary, the dissolved air may be removed by depressurizing or vacuum defoaming thereafter. From the viewpoint of efficiently removing gas (air bubbles), the degree of vacuum at the time of defoaming under reduced pressure is preferably 5 kPa or more and 30 kPa or less. Since gelatin is water-soluble, it can be spun in an aqueous solution as a spinning solution, and the safety to the living body is improved. As the water, for example, pure water, distilled water, ultrapure water or the like can be appropriately used. When another biocompatible water-soluble polymer is used as another component, a spinning solution can be prepared by dissolving it in water at the same time as gelatin.
前記紡糸液の温度は20℃以上90℃以下であることが好ましく、40℃以上90℃以下であることがより好ましい。前記の範囲であればゼラチンは安定したゾル状態を維持できる。また、前記ゼラチン水溶液のゼラチン濃度は、ゼラチン水溶液を100質量%とした時、30質量%以上55質量%以下であることが好ましい。さらに好ましい濃度は35質量%以上50質量%以下である。前記の濃度であれば安定したゾル状態を維持できる。前記ゼラチン水溶液(紡糸液)の粘度は500mPa・s以上3000mPa・s以下が好ましい。ゼラチン水溶液の粘度が前記の範囲であれば安定した紡糸ができる。 The temperature of the spinning liquid is preferably 20 ° C. or higher and 90 ° C. or lower, and more preferably 40 ° C. or higher and 90 ° C. or lower. Within the above range, gelatin can maintain a stable sol state. The gelatin concentration of the gelatin aqueous solution is preferably 30% by mass or more and 55% by mass or less when the gelatin aqueous solution is 100% by mass. A more preferable concentration is 35% by mass or more and 50% by mass or less. At the above concentration, a stable sol state can be maintained. The viscosity of the gelatin aqueous solution (spinning solution) is preferably 500 mPa · s or more and 3000 mPa · s or less. Stable spinning can be achieved if the viscosity of the gelatin aqueous solution is within the above range.
前記紡糸液を紡糸機のノズルから吐出し、前記ノズル周囲から圧力流体を供給し、前記吐出したゼラチン水溶液を前記圧力流体に随伴させて繊維形成させ、得られたゼラチン繊維をゼラチンフィルム上で集積させてゼラチン不織布とする。ノズルの吐出圧は、特に限定されないが、例えば0.1MPa以上1MPa以下であってもよい。 The spinning liquid is discharged from a nozzle of a spinning machine, a pressure fluid is supplied from around the nozzle, the discharged gelatin aqueous solution is associated with the pressure fluid to form fibers, and the obtained gelatin fibers are accumulated on a gelatin film. To make a gelatin non-woven fabric. The discharge pressure of the nozzle is not particularly limited, but may be, for example, 0.1 MPa or more and 1 MPa or less.
前記圧力流体の温度は、20℃以上120℃以下であることが好ましく、80℃以上120℃以下であることがより好ましい。圧力流体の流速及び周囲雰囲気の温度にもよるが、前記の温度範囲であれば安定した紡糸ができる。圧力流体は空気を使用することが好ましく、圧力は0.1MPa以上1MPa以下であることが好ましい。前記の範囲であれば、ノズル吐出口から空気中に押し出された紡糸液を吹き飛ばして繊維化できる。 The temperature of the pressure fluid is preferably 20 ° C. or higher and 120 ° C. or lower, and more preferably 80 ° C. or higher and 120 ° C. or lower. Although it depends on the flow velocity of the pressure fluid and the temperature of the ambient atmosphere, stable spinning can be achieved within the above temperature range. Air is preferably used as the pressure fluid, and the pressure is preferably 0.1 MPa or more and 1 MPa or less. Within the above range, the spinning liquid extruded into the air from the nozzle discharge port can be blown off to form fibers.
前記ゼラチン不織布において、ゼラチン繊維の膨潤後の平均繊維径は2μm以上400μm以下であり、好ましくは5μm以上300μm以下であり、より好ましくは10μm以上200μm以下であり、さらに好ましくは15μm以上100μm以下である。ノズル径(内径)等適宜を調整することで、所望の平均繊維径を有する前記ゼラチン不織布を得ることができる。 In the gelatin non-woven fabric, the average fiber diameter after swelling of gelatin fibers is 2 μm or more and 400 μm or less, preferably 5 μm or more and 300 μm or less, more preferably 10 μm or more and 200 μm or less, and further preferably 15 μm or more and 100 μm or less. .. The gelatin non-woven fabric having a desired average fiber diameter can be obtained by appropriately adjusting the nozzle diameter (inner diameter) and the like.
前記ゼラチン不織布及びゼラチンフィルムの積層体は、架橋することが好ましい。これにより形態安定性及び耐水性を高めることができる。架橋は、架橋剤等の化合物を用いた化学架橋であってもよいが、生体安全性の観点から、生体安全性を有する架橋剤を用いる架橋、架橋剤を用いない架橋であることが好ましい。架橋剤を用いない架橋としては、例えば、熱架橋、電子線架橋、γ線等の放射線架橋、紫外線架橋等が挙げられる。電子線照射、γ線等の放射線照射の場合は、滅菌と架橋を同時にすることもできる。簡便に所望の架橋効果を得やすい観点から、熱架橋であることが好ましく、熱脱水架橋であることがより好ましい。熱脱水架橋は、例えば、100℃以上160℃以下で、24時間以上96時間以下行ってもよい。また、熱脱水架橋は、例えば、1kPa以下の真空下で行ってもよい。前記積層体は、架橋する前に乾燥してもよい。乾燥は、室温における風乾でもよく、真空凍結乾燥でもよい。 The laminate of the gelatin non-woven fabric and the gelatin film is preferably crosslinked. Thereby, morphological stability and water resistance can be improved. The cross-linking may be a chemical cross-linking using a compound such as a cross-linking agent, but from the viewpoint of biosafety, a cross-linking using a cross-linking agent having biosafety or a cross-linking without using a cross-linking agent is preferable. Examples of cross-linking without using a cross-linking agent include thermal cross-linking, electron beam cross-linking, radiation cross-linking such as γ-rays, and ultraviolet cross-linking. In the case of electron beam irradiation or radiation irradiation such as γ-rays, sterilization and cross-linking can be performed at the same time. From the viewpoint of easily obtaining the desired crosslinking effect, thermal crosslinking is preferable, and thermal dehydration crosslinking is more preferable. The thermal dehydration crosslinking may be performed, for example, at 100 ° C. or higher and 160 ° C. or lower for 24 hours or longer and 96 hours or shorter. Further, the thermal dehydration crosslinking may be performed under a vacuum of 1 kPa or less, for example. The laminate may be dried before cross-linking. The drying may be air drying at room temperature or vacuum freeze drying.
ゼラチン不織布とゼラチンフィルムが一体化された積層体を必要に応じて所定の形状や大きさにカットして細胞培養用立体足場として用いることができる。ゼラチンは生体適合性、生分解性を有することから、ゼラチン不織布とゼラチンフィルムが一体化された積層体は、医療用又は細胞培養の足場用に好適である。細胞培養用立体足場は、使用時に、エチレンオキサイドガス滅菌、水蒸気(オートクレーブ)、電子線照射、γ線等の放射線照射等で滅菌したり、エタノール処理等で殺菌することができる。電子線照射、γ線等の放射線照射の場合は、滅菌とともに架橋を同時にすることもできる。 A laminate in which a gelatin non-woven fabric and a gelatin film are integrated can be cut into a predetermined shape and size as needed and used as a three-dimensional scaffold for cell culture. Since gelatin has biocompatibility and biodegradability, a laminate in which a gelatin non-woven fabric and a gelatin film are integrated is suitable for medical use or a scaffold for cell culture. At the time of use, the three-dimensional scaffold for cell culture can be sterilized by ethylene oxide gas sterilization, steam (autoclave), electron beam irradiation, irradiation with γ-rays or the like, or by ethanol treatment or the like. In the case of electron beam irradiation and radiation irradiation such as γ-rays, cross-linking can be performed at the same time as sterilization.
上記ゼラチンフィルムや積層体の製造工程は、例えば、クリーンベンチ、クリーンルーム内で無菌的に行うことが好ましい。作業中における雑菌の繁殖によって、ゼラチンフィルムや積層体が汚染することを防止することができる。使用する製造器具は、例えば、オートクレーブ、電子線照射、γ線等の放射線照射等で滅菌処理されたものを使用することが好ましい。また、上記ゼラチン溶液も、例えば、従来公知のフィルターろ過滅菌を行ってから前記フィルム製造工程に供することが好ましい。 The manufacturing process of the gelatin film or the laminate is preferably performed aseptically in, for example, a clean bench or a clean room. It is possible to prevent the gelatin film and the laminate from being contaminated by the propagation of various germs during the work. As the manufacturing instrument to be used, for example, it is preferable to use one that has been sterilized by autoclave, electron beam irradiation, irradiation with γ-rays or the like. Further, it is preferable that the gelatin solution is also subjected to, for example, conventionally known filter filtration sterilization and then subjected to the film manufacturing process.
本発明において、一例として、架橋させた後の積層体を所定の形に打ち抜く等して成形し、細胞培養用足場とする。或いは、水、緩衝液又は所定の液体培地で膨潤した後に、目的の細胞培養用足場とする。 In the present invention, as an example, the crosslinked laminate is formed by punching into a predetermined shape to obtain a scaffold for cell culture. Alternatively, after swelling with water, a buffer solution or a predetermined liquid medium, the scaffold for target cell culture is used.
前記細胞培養用足場を用いて細胞播種を行うと、足場からの細胞の脱落が抑制され、播種効率が高まる。具体的には、培養容器中に膨潤後の細胞培養用立体足場をゼラチンフィルムが培養容器の内底面に接するように配置し、細胞培養用立体足場のゼラチン不織布上に細胞懸濁液を滴下することで、細胞を播種することができる。足場の配置は、具体的には、ピンセットで足場の端部を把持して行うことができる。 When cell seeding is performed using the cell culture scaffold, the shedding of cells from the scaffold is suppressed and the seeding efficiency is increased. Specifically, the three-dimensional scaffold for cell culture after swelling is placed in the culture vessel so that the gelatin film is in contact with the inner bottom surface of the culture vessel, and the cell suspension is dropped onto the gelatin non-woven fabric of the three-dimensional scaffold for cell culture. This allows the cells to be seeded. Specifically, the scaffold can be arranged by gripping the end of the scaffold with tweezers.
培養容器としては、特に限定されないが、例えば、ディッシュ、プレート、及びフラスコ等を用いることができる。細胞接着を促進するために内面を親水化処理した培養容器であってもよく、このような処理を行っていない未処理培養容器であってもよい。 The culture vessel is not particularly limited, and for example, a dish, a plate, a flask, or the like can be used. A culture vessel whose inner surface has been hydrophilized in order to promote cell adhesion may be used, or an untreated culture vessel which has not been subjected to such treatment may be used.
培養容器として、細胞接着を促進するために内底面等の内面を親水化処理した培養容器を用いる場合は、前記細胞培養用立体足場の膨潤後のサイズ(例えば、直径)Lsと前記細胞培養用立体足場を配置して細胞培養を行う培養容器の内底面のサイズ(例えば、直径)Lbの比Ls/Lbが1.01倍以上1.30倍以下であることが好ましく、1.05培以上1.25倍以下であることがより好ましく、1.10倍以上1.20倍以下であることがさらに好ましい。これにより、細胞培養用立体足場と培養容器の側面との密着性が良好になり、細胞播種時に細胞が足場の周囲を回り込んで足場から脱落することが抑制される。ここで、Ls及びLbは、それぞれ、膨潤後の細胞培養用立体足場をゼラチンフィルムが培養容器の内底面に接するように配置した後、所定の配置箇所において測定した培養容器の内底面のサイズ及びその配置箇所における細胞培養用立体足場の膨潤後のサイズを意味する。例えば、培養容器の内底面が円形の場合は、細胞培養用立体足場の膨潤後のサイズLsは細胞培養用立体足場の膨潤後の直径に該当し、培養容器の内底面のサイズLbは培養容器の内底面の直径に該当する。 When a culture vessel in which the inner surface such as the inner bottom surface is hydrophilized in order to promote cell adhesion is used as the culture vessel, the size (for example, diameter) Ls of the three-dimensional scaffold for cell culture after swelling and the cell culture The ratio Ls / Lb of the size (for example, diameter) Lb of the inner bottom surface of the culture vessel in which the three-dimensional scaffold is arranged and the cells are cultured is preferably 1.01 times or more and 1.30 times or less, preferably 1.05 times or more. It is more preferably 1.25 times or less, and further preferably 1.10 times or more and 1.20 times or less. As a result, the adhesion between the three-dimensional scaffold for cell culture and the side surface of the culture vessel is improved, and it is suppressed that the cells wrap around the scaffold and fall off from the scaffold at the time of cell seeding. Here, for Ls and Lb, the size of the inner bottom surface of the culture vessel and the size of the inner bottom surface of the culture vessel measured at a predetermined arrangement location after arranging the three-dimensional scaffold for cell culture after swelling so that the gelatin film is in contact with the inner bottom surface of the culture vessel, respectively. It means the size of the three-dimensional scaffold for cell culture after swelling at the place of arrangement. For example, when the inner bottom surface of the culture vessel is circular, the size Ls after swelling of the three-dimensional scaffold for cell culture corresponds to the diameter after swelling of the three-dimensional scaffold for cell culture, and the size Lb of the inner bottom surface of the culture vessel is the culture vessel. Corresponds to the diameter of the inner bottom surface of.
本発明において、細胞は、動物細胞であればよく、その由来は特に限定されない。動物としては、ヒトでもよく、ヒト以外の動物でもよい。ヒト以外の動物としては、例えば、サル、チンパンジー等の霊長類、マウス、ラット、ハムスター等の齧歯類、ウシ、ヒツジ、ヤギ、ブタ等の有蹄類等が挙げられる。また、本発明において、細胞は、個々の細胞、細胞株、初代培養等培養で得られる細胞等を含む。前記細胞としては、特に限定されないが、例えば、体細胞、幹細胞、前駆細胞、生殖細胞、免疫細胞等が挙げられる。 In the present invention, the cell may be an animal cell, and its origin is not particularly limited. The animal may be a human or a non-human animal. Examples of animals other than humans include primates such as monkeys and chimpanzees, rodents such as mice, rats and hamsters, and ungulates such as cows, sheep, goats and pigs. Further, in the present invention, the cells include individual cells, cell lines, cells obtained by culturing such as primary culture, and the like. The cells are not particularly limited, and examples thereof include somatic cells, stem cells, progenitor cells, germ cells, immune cells, and the like.
体細胞は、生体を構成する体細胞や体細胞から派生した癌細胞を含む。生体を構成する体細胞としては、特に限定されず、例えば、線維芽細胞、筋細胞、内皮細胞、骨芽細胞、内皮細胞、膀胱細胞、肺細胞、骨細胞、神経細胞、肝細胞、軟骨細胞、上皮細胞、中皮細胞等が挙げられる。癌細胞としては、特に限定されず、例えば、乳癌細胞、腎癌細胞、前立腺癌細胞、肺癌細胞、肝癌細胞、子宮頸癌細胞、食道上皮癌、膵癌、大腸癌、膀胱癌等が挙げられる。 Somatic cells include somatic cells that make up a living body and cancer cells derived from somatic cells. The somatic cells constituting the living body are not particularly limited, and are, for example, fibroblasts, muscle cells, endothelial cells, osteoblasts, endothelial cells, bladder cells, lung cells, osteoblasts, nerve cells, hepatocytes, and chondrocytes. , Epithelial cells, mesenteric cells and the like. The cancer cells are not particularly limited, and examples thereof include breast cancer cells, renal cancer cells, prostate cancer cells, lung cancer cells, liver cancer cells, cervical cancer cells, esophageal epithelial cancer, pancreatic cancer, colon cancer, and bladder cancer.
幹細胞は、様々な特殊化した細胞型へ分化する可能性がある細胞である。幹細胞としては、特に限定されず、例えば、胚性幹細胞(ES細胞)、胚性癌腫細胞(EC)、胚性生殖幹細胞(EG)、人工多能性幹細胞(iPS細胞)、成体幹細胞、胚盤胞由来幹細胞、生殖隆起由来幹細胞、奇形腫由来幹細胞、オンコスタチン非依存性幹細胞(OISC)、骨髄由来間葉系幹細胞、脂肪由来間葉系幹細胞、羊水由来間葉系幹細胞、皮膚由来間葉系幹細胞、骨膜由来間葉系幹細胞等が挙げられる。 Stem cells are cells that can differentiate into a variety of specialized cell types. The stem cells are not particularly limited, and are, for example, embryonic stem cells (ES cells), embryonic cancer tumor cells (EC), embryonic germ stem cells (EG), artificial pluripotent stem cells (iPS cells), adult stem cells, and scutellum. Spore-derived stem cells, reproductive ridge-derived stem cells, malformation-derived stem cells, oncostatin-independent stem cells (OISC), bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, sheep water-derived mesenchymal stem cells, skin-derived mesenchymal stem cells Examples thereof include stem cells and bone membrane-derived mesenchymal stem cells.
前駆細胞は、前記幹細胞から発生し生体を構成する最終分化細胞へ分化することができる細胞である。 Progenitor cells are cells that can develop from the stem cells and differentiate into terminally differentiated cells that constitute a living body.
生殖細胞としては、精子、精細胞、卵子、卵細胞等が挙げられる。 Examples of germ cells include sperm, sperm cells, eggs, and egg cells.
免疫細胞としては、特に限定されないが、例えば、マクロファージ、リンパ球、樹状細胞等が挙げられる。 The immune cell is not particularly limited, and examples thereof include macrophages, lymphocytes, and dendritic cells.
上述した細胞は、1種を単独で用いてもよく、目的等に応じて2種以上を併用してもよい。 As the above-mentioned cells, one type may be used alone, or two or more types may be used in combination depending on the purpose and the like.
細胞培養用立体足場の単位表面積当たりの細胞の播種量は、特に限定されず、細胞種類、足場の厚み及び目付等に基づいて適宜決めることができるが、例えば、高密度に播種する観点から、200細胞/mm2以上20000細胞/cm2以下であることが好ましく、2000細胞/mm2以上15000細胞/mm2以下であることがより好ましく、4000細胞/mm2以上12000細胞/mm2以下であることがさらに好ましい。 The seeding amount of cells per unit surface area of the three-dimensional scaffold for cell culture is not particularly limited and can be appropriately determined based on the cell type, the thickness of the scaffold, the texture, etc. 200 cells / mm 2 or more and 20000 cells / cm 2 or less, 2000 cells / mm 2 or more and 15000 cells / mm 2 or less, 4000 cells / mm 2 or more and 12000 cells / mm 2 or less It is more preferable to have.
前記液体培地としては、特に限定されず、細胞の種類に応じて、細胞の生存増殖に必要な成分を含むものを適宜用いることができる。前記培地は、血清、抗生物質及び成長因子等を含んでもよい。血清は、例えば、ウシ血清、ウシ胎児血清、ウマ血清、ヒト血清等を適宜用いることができる。抗生物質は、ペニシリン、ストレプトマイシン、ゲンタマイシン、アンフォテリシン、アンピシリン、ミノマイシン、カナマイシン等を適宜用いることができる。成長因子は、細胞増殖因子、分化誘導因子、細胞接着因子等を適宜用いることができる。 The liquid medium is not particularly limited, and a medium containing components necessary for the survival and proliferation of cells can be appropriately used depending on the type of cells. The medium may contain serum, antibiotics, growth factors and the like. As the serum, for example, bovine serum, fetal bovine serum, horse serum, human serum and the like can be appropriately used. As the antibiotic, penicillin, streptomycin, gentamicin, amphotericin, ampicillin, minocycline, kanamycin and the like can be appropriately used. As the growth factor, a cell proliferation factor, a differentiation inducing factor, a cell adhesion factor and the like can be appropriately used.
本発明の1以上の実施形態において、細胞培養用立体足場のゼラチン不織布上に細胞懸濁液を滴下した後、所定時間例えば3〜4時間静置して細胞を接着させるための前培養を行った後に、液体培地を添加して細胞培養を行うことができる。 In one or more embodiments of the present invention, after dropping the cell suspension on the gelatin non-woven fabric of the three-dimensional scaffold for cell culture, the cells are allowed to stand for a predetermined time, for example, 3 to 4 hours, and precultured to adhere the cells. After that, a liquid medium can be added to carry out cell culture.
培養は、例えば、27℃以上40℃以下で行ってもよく、31℃以上37℃以下であってもよい。二酸化炭素は、2%以上10%以下の範囲であってもよい。 The culture may be carried out at, for example, 27 ° C. or higher and 40 ° C. or lower, or 31 ° C. or higher and 37 ° C. or lower. Carbon dioxide may be in the range of 2% or more and 10% or less.
培養時間は、細胞種類、細胞数等に応じて適宜決めればよいが、例えば、2〜8日継続して培養してもよく、3〜7日継続して行ってもよく、4〜6日継続して行ってもよい。培地は、2〜3日毎に交換してもよい。 The culturing time may be appropriately determined according to the cell type, the number of cells, etc., but for example, the culturing may be continued for 2 to 8 days, continuously for 3 to 7 days, or 4 to 6 days. You may continue to do so. The medium may be changed every 2-3 days.
一例として、細胞播種4時間後に細胞が細胞培養用立体足場に接着したのを確認してから、培養容器中に液体培地を加え、所定条件(例えば温度37℃、5%CO2)のインキュベーター中で静置培養してもよい。液体培地は、2〜3日毎に交換してもよい。或いは、細胞播種後に、培養容器中に液体培地を加え、37℃、5%CO2のインキュベーター中に置いたマグネティックスターラー上で液体培地を撹拌して循環させながら、撹拌培養してもよい。3〜4日毎に、液体培地を半分量除き、等量の新たな液体培地を加えることで、培地交換を行ってもよい。或いは、細胞播種後に、培養容器中に液体培地を加え、37℃、5%CO2のインキュベーター中で振とうさせながら培養してもよい。3〜4日毎に、液体培地を半分量除き、等量の新たな液体培地を加えることで、培地交換を行ってもよい。本発明の細胞培養用立体足場は、水に濡れると透明になるため、培養液中で倒立顕微鏡により足場の内部まで観察することができる。 As an example, after confirming that the cells adhered to the three-dimensional scaffold for cell culture 4 hours after cell seeding, a liquid medium was added to the culture vessel, and the cells were placed in an incubator under predetermined conditions (for example, temperature 37 ° C., 5% CO 2). May be statically cultured in. The liquid medium may be changed every 2-3 days. Alternatively, after cell seeding, a liquid medium may be added to a culture vessel, and the liquid medium may be stirred and cultured on a magnetic stirrer placed in an incubator at 37 ° C. and 5% CO 2 while stirring and culturing. Medium may be replaced every 3-4 days by removing half the amount of liquid medium and adding an equal amount of fresh liquid medium. Alternatively, after cell seeding, a liquid medium may be added to the culture vessel, and the cells may be cultured while shaking in an incubator at 37 ° C. and 5% CO 2. Medium may be replaced every 3-4 days by removing half the amount of liquid medium and adding an equal amount of fresh liquid medium. Since the three-dimensional scaffold for cell culture of the present invention becomes transparent when it gets wet with water, the inside of the scaffold can be observed with an inverted microscope in the culture solution.
上記のように細胞培養用立体足場に細胞を播種し、細胞培養を行うと、細胞が足場内部に侵入しやすく、細胞が足場からの脱落が抑制されていることから、安定的に目的とする3次元細胞を行うことができる。 When cells are seeded on a three-dimensional scaffold for cell culture as described above and cell culture is performed, the cells easily invade the inside of the scaffold and the cells are suppressed from falling off from the scaffold. Three-dimensional cells can be made.
以下、実施例を用いてさらに具体的に説明する。なお、本発明は下記の実施例に限定されるものではない。 Hereinafter, a more specific description will be given with reference to Examples. The present invention is not limited to the following examples.
測定・評価方法は下記のとおりである。
<平均繊維径>
膨潤後の足場を光学顕微鏡(株式会社キーエンス社製、型番BZ−X700)で観察し、任意に選択した50本の繊維を用いて、膨潤後の平均繊維径を測定した。
<厚み>
積層体の断面を走査型電子顕微鏡(日立ハイテクノロジーズ製FlexSEM1000、100倍及び500倍)で観察し、得られた走査型電子顕微鏡写真から任意に選択した10か所のゼラチンフィルム層厚み、ゼラチン不織布の厚み、及び積層体の厚みを計測し、平均値を算出した。
<目付(単位面積あたりの質量)>
ゼラチン不織布の目付はJIS L 1913に準じて測定した。
<見掛密度>
ゼラチン不織布の密度は不織布の厚み及び目付に基づいて算出した。
<細孔径>
ゼラチン不織布の細孔径は、Wrotnowskiの仮定に基づいて、下記計算式(1)にて算出することができる。
<Average fiber diameter>
The scaffold after swelling was observed with an optical microscope (manufactured by KEYENCE CORPORATION, model number BZ-X700), and the average fiber diameter after swelling was measured using 50 fibers arbitrarily selected.
<Thickness>
The cross section of the laminate was observed with a scanning electron microscope (FlexSEM1000 manufactured by Hitachi High-Technologies Corporation, 100 times and 500 times), and 10 gelatin film layer thicknesses and gelatin non-woven fabrics were arbitrarily selected from the obtained scanning electron micrographs. And the thickness of the laminated body were measured, and the average value was calculated.
<Metsuke (mass per unit area)>
The basis weight of the gelatin non-woven fabric was measured according to JIS L 1913.
<Apparent density>
The density of the gelatin non-woven fabric was calculated based on the thickness and basis weight of the non-woven fabric.
<Pore diameter>
The pore diameter of the gelatin non-woven fabric can be calculated by the following formula (1) based on the assumption of Wrotnowski.
(実施例1)
<積層体(細胞培養用立体足場)の作製>
ゼラチンとして新田ゼラチン社製(ゼリー強度262g、原料:アルカリ処理牛骨)を使用し、ゼラチン:水=92.5:7.5の質量比(ゼラチン濃度7.5質量%)とし、温度60℃で溶解した。このゼラチン水溶液を、ポリテトラフルオロエチレンフィルム(膜厚50μm)上に、TP技研株式会社製バーコーターNo.20で塗布し、室温で一晩風乾させることによりゼラチンフィルムを得た。
次いで、ゼラチンとして新田ゼラチン社製(ゼリー強度262g、原料:アルカリ処理牛骨)を使用し、ゼラチン:水=3:5の質量比(ゼラチン濃度37.5質量%)とし、温度60℃で溶解した。60℃における粘度は960〜970mPa・sであった。このゼラチン水溶液を紡糸液とし、図10に示す製造装置を使用して、巻き取りロール上に配置されたゼラチンフィルム上にゼラチン繊維を集積して不織布にすることで積層体を製造した。紡糸液の温度は60℃、ノズル直径(内径)250μm、吐出圧0.2MPa、ノズル高さ5mm、エアー圧力0.375MPa、エアー温度100℃、流体噴射口とノズル吐出口との距離は5mm、捕集距離50cmとした。積層体は室温で一晩風乾し、次いで加熱脱水架橋させた。架橋条件は温度140℃、48時間とした。
得られた積層体を精製水で膨潤後に直径7mmの円柱に打ち抜き、細胞培養用立体足場を作製した。
なお、積層体において、ゼラチン不織布の目付は150g/m2、ゼラチン繊維の膨潤後の平均繊維径は47μm、孔径は119.6〜157.1μmであった。
<細胞播種>
(1)上記で得られた積層体(細胞培養用立体足場)を液体培地(Gibco社製のMEM Alpha basic)中に30分間静置して、液体培地で膨潤させた。
(2)膨潤後の積層体をゼラチンフィルムがウェルの底面に接するようにウェル底面の直径が6.3mmの96ウェルプレート中に設置した。70%エタノールで洗浄し、PBSで洗浄することで積層体を殺菌した。
(3)積層体をつついて、確実にウェル底面・壁面に密着させて泡がないようにした。
(4)マウス由来の繊維芽細胞様MC3T3−E1細胞を液体培地(Gibco社製 MEM Alpha basic)に1×106cells/mLになるように懸濁して得られた細胞懸濁液を積層体のゼラチン不織布の表面上に100μL滴下した。温度37℃、5%CO2のインキュベーター中で4時間静置培養して細胞を積層体に接着させた後、液体培地100μLをさらに添加した。
(5)ウェル底面にピントを合わせて光学顕微鏡(オリンパス社製、型番CKX53)で明視野観察し、積層体の反り、及びウェル底面及び壁面への密着性を観察した。
(6)積層体を慎重に除去し、ウェル底面に落ちた細胞を光学顕微鏡(株式会社キーエンス社製、型番BZ−X700)で明視野観察した。ウェル底面を明視野観察写真において、1/4面積(即ち90°)分を抽出し、細胞の接着面積をImage Jで測定し、ウェルの1/4面積の中の細胞接着面積の割合を算出した。
(7)積層体を4%パラホルムアルデヒド(PFA)固定し、50℃の送風乾燥機で2〜3時間乾燥した後、ゼラチンフィルム部を走査型電子顕微鏡(日立ハイテクノロジーズ製FlexSEM1000、500倍)で観察し、ゼラチンフィルムの破れの有無を確認した。
(8)積層体を4%PFA固定後、さらにリン酸緩衝液(pH7.4)で洗浄した。洗浄後、OCTコンパウンド(サクラファインテックジャパン社)で包埋後、液体窒素で凍結し、凍結状態で、円柱状の積層体の直径と垂直方向(積層体の最大割面)を10μm厚になるように切片を作製した。切片の作製にはクライオフィルム(ライカマイクロシステムズ社製、型番「2C(9)」)を用いた。凍結切片をヘマトキシリンエオジン染色し、足場内の細胞分布の仕方を光学顕微鏡(株式会社キーエンス社製、型番「BZ−X700」)で観察した。
(Example 1)
<Preparation of laminate (three-dimensional scaffold for cell culture)>
Nitta Gelatin Co., Ltd. (jelly strength 262 g, raw material: alkali-treated beef bone) was used as gelatin, and the mass ratio of gelatin: water = 92.5: 7.5 (gelatin concentration 7.5% by mass) was used, and the temperature was 60. Dissolved at ° C. This gelatin aqueous solution was placed on a polytetrafluoroethylene film (thickness: 50 μm) on a bar coater No. 1 manufactured by TP Giken Co., Ltd. A gelatin film was obtained by applying at 20 and air-drying at room temperature overnight.
Next, using Nitta Gelatin Co., Ltd. (jelly strength 262 g, raw material: alkali-treated beef bone) as gelatin, the mass ratio of gelatin: water = 3: 5 (gelatin concentration 37.5 mass%) was set, and the temperature was 60 ° C. Dissolved. The viscosity at 60 ° C. was 960-970 mPa · s. A laminate was produced by using this aqueous gelatin solution as a spinning solution and using the production apparatus shown in FIG. 10 to accumulate gelatin fibers on a gelatin film arranged on a take-up roll to form a non-woven fabric. The temperature of the spinning liquid is 60 ° C, the nozzle diameter (inner diameter) is 250 μm, the discharge pressure is 0.2 MPa, the nozzle height is 5 mm, the air pressure is 0.375 MPa, the air temperature is 100 ° C, and the distance between the fluid injection port and the nozzle discharge port is 5 mm. The collection distance was 50 cm. The laminate was air dried overnight at room temperature and then heat dehydrated and crosslinked. The cross-linking conditions were a temperature of 140 ° C. and 48 hours.
The obtained laminate was swollen with purified water and then punched into a cylinder having a diameter of 7 mm to prepare a three-dimensional scaffold for cell culture.
In the laminated body, the weight of the gelatin non-woven fabric was 150 g / m 2 , the average fiber diameter after swelling of the gelatin fibers was 47 μm, and the pore diameter was 119.6 to 157.1 μm.
<Cell seeding>
(1) The laminate (three-dimensional scaffold for cell culture) obtained above was allowed to stand in a liquid medium (MEM Alpha basic manufactured by Gibco) for 30 minutes and swollen in the liquid medium.
(2) The swelled laminate was placed in a 96-well plate having a diameter of 6.3 mm at the bottom of the well so that the gelatin film was in contact with the bottom of the well. The laminate was sterilized by washing with 70% ethanol and washing with PBS.
(3) The laminate was pecked to ensure that it was in close contact with the bottom surface and wall surface of the well to prevent bubbles.
(4) A laminate obtained by suspending mouse-derived fibroblast-like MC3T3-E1 cells in a liquid medium (MEM Alpha basic manufactured by Gibco) so as to have a concentration of 1 × 10 6 cells / mL. 100 μL was added dropwise on the surface of the gelatin non-woven fabric. After allowing the cells to adhere to the laminate by static culture for 4 hours in an incubator at a temperature of 37 ° C. and 5% CO 2, 100 μL of liquid medium was further added.
(5) Focusing on the bottom surface of the well, bright field observation was performed with an optical microscope (manufactured by Olympus Corporation, model number CKX53), and the warp of the laminate and the adhesion to the bottom surface and the wall surface of the well were observed.
(6) The laminate was carefully removed, and the cells that fell on the bottom surface of the well were observed in a bright field with an optical microscope (manufactured by KEYENCE CORPORATION, model number BZ-X700). A 1/4 area (that is, 90 °) of the well bottom surface is extracted in a bright field observation photograph, the cell adhesion area is measured by Image J, and the ratio of the cell adhesion area to the 1/4 area of the well is calculated. did.
(7) The laminate was fixed with 4% paraformaldehyde (PFA), dried in a blower dryer at 50 ° C. for 2 to 3 hours, and then the gelatin film portion was subjected to a scanning electron microscope (FlexSEM1000 manufactured by Hitachi High-Technologies Corporation, 500 times). By observing, it was confirmed whether or not the gelatin film was torn.
(8) The laminate was fixed with 4% PFA and then further washed with a phosphate buffer solution (pH 7.4). After cleaning, it is embedded in OCT compound (Sakura Finetech Japan Co., Ltd.), frozen in liquid nitrogen, and in the frozen state, the diameter of the columnar laminate and the vertical direction (maximum split plane of the laminate) become 10 μm thick. Sections were prepared as described above. A cryofilm (manufactured by Leica Microsystems, model number "2C (9)") was used to prepare the sections. Frozen sections were stained with hematoxylin eosin, and the cell distribution in the scaffold was observed with an optical microscope (manufactured by KEYENCE CORPORATION, model number "BZ-X700").
(実施例2)
ゼラチンフィルム作製時のゼラチン水溶液の濃度を5質量%とした以外は、実施例1と同様にして、細胞培養用立体足場を作製し、細胞播種を行った。
(Example 2)
A three-dimensional scaffold for cell culture was prepared and cell seeding was carried out in the same manner as in Example 1 except that the concentration of the gelatin aqueous solution at the time of preparing the gelatin film was 5% by mass.
(実施例3)
ゼラチンフィルム作製時にTP技研株式会社製バーコーターNo.10を使用した以外は、実施例2と同様にして、細胞培養用立体足場を作製し、細胞播種を行った。
(Example 3)
When making gelatin film, TP Giken Co., Ltd. Bar Coater No. A three-dimensional scaffold for cell culture was prepared and cell seeding was carried out in the same manner as in Example 2 except that No. 10 was used.
(比較例1)
ゼラチンフィルム作製時にTP技研株式会社製バーコーターNo.40を使用した以外は実施例2と同様にして、細胞培養用立体足場を作製し、細胞播種を行った。
(Comparative Example 1)
When making gelatin film, TP Giken Co., Ltd. Bar Coater No. A three-dimensional scaffold for cell culture was prepared and cell seeding was carried out in the same manner as in Example 2 except that 40 was used.
(比較例2)
ゼラチンとして新田ゼラチン社製(ゼリー強度262g 原料:アルカリ処理牛骨)を使用し、ゼラチン:水=3:5の質量比(ゼラチン濃度37.5質量%)とし、温度60℃で溶解した。60℃における粘度は960〜970mPa・sであった。このゼラチン水溶液を紡糸液とし、図10に示す製造装置を使用して、巻き取りロール上に直接ゼラチン繊維を集積して長繊維不織布を製造した。紡糸液の温度は60℃、ノズル直径(内径)250μm、吐出圧0.2MPa、ノズル高さ5mm、エアー圧力0.375MPa、エアー温度100℃、流体噴射口とノズル吐出口との距離は5mm、捕集距離50cmとした。長繊維不織布は室温で一晩風乾し、次いで加熱脱水架橋させた。架橋条件は温度140℃、48時間とした。
得られたゼラチン不織布の目付は150g/m2、ゼラチン繊維の膨潤後の平均繊維径は47μm、孔径は119.6〜157.1μmであった。
得られた長繊維不織布を精製水で膨潤後に直径φ7mmの円柱に打ち抜き、細胞培養用立体足場を作製した。
上記で得られた細胞培養用立体足場を用いた以外は、実施例1と同様にして細胞播種を行った。
(Comparative Example 2)
As gelatin, a product manufactured by Nitta Gelatin Co., Ltd. (jelly strength 262 g, raw material: alkali-treated beef bone) was used, the mass ratio was gelatin: water = 3: 5 (gelatin concentration 37.5 mass%), and the mixture was dissolved at a temperature of 60 ° C. The viscosity at 60 ° C. was 960-970 mPa · s. Using this aqueous gelatin solution as a spinning solution, gelatin fibers were directly accumulated on a take-up roll using the production apparatus shown in FIG. 10 to produce a long-fiber non-woven fabric. The temperature of the spinning liquid is 60 ° C, the nozzle diameter (inner diameter) is 250 μm, the discharge pressure is 0.2 MPa, the nozzle height is 5 mm, the air pressure is 0.375 MPa, the air temperature is 100 ° C, and the distance between the fluid injection port and the nozzle discharge port is 5 mm. The collection distance was 50 cm. The long fiber non-woven fabric was air dried overnight at room temperature and then heat dehydrated and crosslinked. The cross-linking conditions were a temperature of 140 ° C. and 48 hours.
The weight of the obtained gelatin non-woven fabric was 150 g / m 2 , the average fiber diameter after swelling of the gelatin fibers was 47 μm, and the pore diameter was 119.6 to 157.1 μm.
The obtained long-fiber non-woven fabric was swollen with purified water and then punched into a cylinder having a diameter of φ7 mm to prepare a three-dimensional scaffold for cell culture.
Cell seeding was carried out in the same manner as in Example 1 except that the three-dimensional scaffold for cell culture obtained above was used.
実施例1及び比較例2の細胞培養用立体足場の各種測定・評価結果を下記表1に示した。下記表1において、厚みは膨潤前の細胞培養用立体足場について測定したものであり、Lsは膨潤後の細胞培養用立体足場の直径について測定したものである。 The results of various measurements and evaluations of the three-dimensional scaffolds for cell culture of Example 1 and Comparative Example 2 are shown in Table 1 below. In Table 1 below, the thickness is measured for the cell culture three-dimensional scaffold before swelling, and Ls is the diameter of the cell culture three-dimensional scaffold after swelling.
表1及び表2のデータから分かるように、ゼラチンフィルムとゼラチン不織布が積層されて一体化された細胞培養用立体足場において、ゼラチンフィルムの厚みTfとゼラチン不織布の厚みTnの比Tf/Tnが7.5×10−3以下である実施例では、細胞播種時に、足場からの細胞の脱落が抑制されており、播種効率が向上していた。 As can be seen from the data in Tables 1 and 2, the ratio Tf / Tn of the thickness Tf of the gelatin film to the thickness Tn of the gelatin non-woven fabric is 7 in the three-dimensional scaffold for cell culture in which the gelatin film and the gelatin non-woven fabric are laminated and integrated. In the examples having a size of .5 × 10 -3 or less, the shedding of cells from the scaffold was suppressed at the time of cell seeding, and the seeding efficiency was improved.
一方、ゼラチンフィルムとゼラチン不織布が積層されて一体化されているが、ゼラチンフィルムの厚みTfとゼラチン不織布の厚みTnの比Tf/Tnが7.5×10−3を超える比較例1の足場の場合、ゼラチンフィルムとゼラチン不織布の膨潤程度の違いにより積層体に反りが発生し、その傾斜によって細胞懸濁液が積層体の側面に流出してしまい、足場からの細胞の脱落が顕著であった。また、ゼラチンフィルムを含んでいない比較例2の足場の場合も、細胞播種後に、足場から細胞が顕著に脱落していた。 On the other hand, although the gelatin film and the gelatin non-woven fabric are laminated and integrated, the scaffold of Comparative Example 1 in which the ratio Tf / Tn of the thickness Tf of the gelatin film and the thickness Tn of the gelatin non-woven fabric exceeds 7.5 × 10 -3. In this case, the laminate was warped due to the difference in the degree of swelling between the gelatin film and the gelatin non-woven fabric, and the inclination caused the cell suspension to flow out to the side surface of the laminate, resulting in significant loss of cells from the scaffold. .. Also, in the case of the scaffold of Comparative Example 2 containing no gelatin film, cells were significantly shed from the scaffold after cell seeding.
(2)細胞の分布
図11に、実施例1において、足場に細胞を播種し、4時間静置して細胞をゼラチン不織布に接着させた後の足場の切片(足場断面)をヘマトキシリンエオジン染色し、光学顕微鏡で観察した全体像の写真(10倍で観察し、ソフトウェア上で連結)を示した。図11において、スケールは1mmである。図12に、ゼラチン不織布部分の拡大写真を示した。図12において、スケールは100μmである。図13に、ゼラチンフィルム部分の拡大写真を示した。図13において、スケールは100μmである。図11〜13から明らかなように、積層体のゼラチン不織布の表面上に播種した細胞が足場内部まで侵入している。
(2) Cell distribution In FIG. 11, in Example 1, cells were seeded on a scaffold, left to stand for 4 hours to adhere the cells to a gelatin non-woven fabric, and then a section of the scaffold (scaffold cross section) was stained with hematoxylin eosin. , A photograph of the whole image observed with an optical microscope (observed at 10 times and connected on software) was shown. In FIG. 11, the scale is 1 mm. FIG. 12 shows an enlarged photograph of the gelatin non-woven fabric portion. In FIG. 12, the scale is 100 μm. FIG. 13 shows an enlarged photograph of the gelatin film portion. In FIG. 13, the scale is 100 μm. As is clear from FIGS. 11 to 13, the cells seeded on the surface of the laminated gelatin non-woven fabric have invaded the inside of the scaffold.
本発明の細胞培養用立体足場は、細胞培養に用いる他、様々な医療用途にも適用できる。 The three-dimensional scaffold for cell culture of the present invention can be applied not only to cell culture but also to various medical uses.
1 加温槽
2 紡糸液
3 ノズル吐出口
4、6 コンプレッサー
5 流体噴射口
7 圧力流体
8 ゼラチン繊維
9 ゼラチン不織布
10 ゼラチンフィルム
11 巻き取りロール
12 保温容器
20 製造装置
1
Claims (9)
前記ゼラチン不織布を構成するゼラチン繊維は、膨潤後の平均繊維径が2μm以上400μm以下であり、繊維交点が少なくとも部分的に溶着しており、
前記ゼラチンフィルムは、前記ゼラチン不織布の一方の表面に積層され、前記ゼラチン不織布を構成するゼラチン繊維と部分的に溶着しており、
前記ゼラチン不織布の厚みTnと前記ゼラチンフィルムの厚みTfとの比Tf/Tnが7.5×10−3以下であることを特徴とする細胞培養用立体足場。 In a three-dimensional scaffold for cell culture composed of a laminate containing a gelatin non-woven fabric containing gelatin as a main component and a gelatin film containing gelatin as a main component.
The gelatin fibers constituting the gelatin non-woven fabric have an average fiber diameter of 2 μm or more and 400 μm or less after swelling, and the fiber intersections are at least partially welded.
The gelatin film is laminated on one surface of the gelatin nonwoven fabric and partially welded to the gelatin fibers constituting the gelatin nonwoven fabric.
A three-dimensional scaffold for cell culture, wherein the ratio Tf / Tn of the thickness Tn of the gelatin non-woven fabric to the thickness Tf of the gelatin film is 7.5 × 10 -3 or less.
ゼラチンを含む紡糸液をノズル吐出口から空気中に押し出し、
前記ノズル吐出口の後方に位置し、前記ノズル吐出口とは非接触状態の流体噴射口から前方に向けて圧力流体を噴射し、
前記押し出された紡糸液を前記圧力流体に随伴させて繊維形成させ、ゼラチンを主成分とするゼラチンフィルム上に前記繊維形成した繊維を集積させてゼラチン不織布とすることで、前記ゼラチンフィルムと前記ゼラチン不織布の積層体を得ることを特徴とする細胞培養用立体足場の製造方法。 The method for producing a three-dimensional scaffold for cell culture according to any one of claims 1 to 4.
The spinning liquid containing gelatin is extruded into the air from the nozzle discharge port,
A pressure fluid is injected forward from a fluid injection port located behind the nozzle discharge port and in a non-contact state with the nozzle discharge port.
The extruded spinning liquid is associated with the pressure fluid to form fibers, and the fiber-formed fibers are accumulated on a gelatin film containing gelatin as a main component to form a gelatin non-woven fabric, whereby the gelatin film and the gelatin are formed. A method for producing a three-dimensional scaffold for cell culture, which comprises obtaining a laminate of non-woven fabric.
培養容器中に膨潤後の細胞培養用立体足場をゼラチンフィルムが培養容器の内底面に接するように配置する工程、及び
細胞培養用立体足場のゼラチン不織布上に細胞懸濁液を滴下する工程を含むことを特徴とする細胞播種方法。 The cell seeding method using the three-dimensional scaffold for cell culture according to any one of claims 1 to 4.
The step of arranging the three-dimensional scaffold for cell culture after swelling in the culture vessel so that the gelatin film is in contact with the inner bottom surface of the culture vessel, and the step of dropping the cell suspension onto the gelatin non-woven fabric of the three-dimensional scaffold for cell culture are included. A cell seeding method characterized by this.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019210643A JP7267172B2 (en) | 2019-11-21 | 2019-11-21 | Three-dimensional scaffold for cell culture, method for producing the same, method for seeding cells using the same, and method for cell culture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019210643A JP7267172B2 (en) | 2019-11-21 | 2019-11-21 | Three-dimensional scaffold for cell culture, method for producing the same, method for seeding cells using the same, and method for cell culture |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021078458A true JP2021078458A (en) | 2021-05-27 |
JP7267172B2 JP7267172B2 (en) | 2023-05-01 |
Family
ID=75961976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019210643A Active JP7267172B2 (en) | 2019-11-21 | 2019-11-21 | Three-dimensional scaffold for cell culture, method for producing the same, method for seeding cells using the same, and method for cell culture |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7267172B2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004148014A (en) * | 2002-10-31 | 2004-05-27 | Nipro Corp | Biodegradable base material and prosthesis for anagenesis, and cultured tissue |
JP2014514942A (en) * | 2011-04-05 | 2014-06-26 | ウニベルジテートスクリニクム フライブルク | Biocompatible and biodegradable gradient layer systems for regenerative medicine and tissue support |
WO2016068266A1 (en) * | 2014-10-31 | 2016-05-06 | 国立大学法人京都大学 | Three-dimensional culture method using biodegradable polymer and culture substrate enabling cell transplantation |
WO2018235745A1 (en) * | 2017-06-20 | 2018-12-27 | 日本毛織株式会社 | Biocompatible long-fiber nonwoven fabric, production method therefor, three-dimensional scaffold for cell culturing, and cell culturing method using same |
JP7038368B2 (en) * | 2019-11-21 | 2022-03-18 | 日本毛織株式会社 | Cell aggregate, its production method, its preparation kit, and method for evaluating compounds using it. |
-
2019
- 2019-11-21 JP JP2019210643A patent/JP7267172B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004148014A (en) * | 2002-10-31 | 2004-05-27 | Nipro Corp | Biodegradable base material and prosthesis for anagenesis, and cultured tissue |
JP2014514942A (en) * | 2011-04-05 | 2014-06-26 | ウニベルジテートスクリニクム フライブルク | Biocompatible and biodegradable gradient layer systems for regenerative medicine and tissue support |
WO2016068266A1 (en) * | 2014-10-31 | 2016-05-06 | 国立大学法人京都大学 | Three-dimensional culture method using biodegradable polymer and culture substrate enabling cell transplantation |
WO2018235745A1 (en) * | 2017-06-20 | 2018-12-27 | 日本毛織株式会社 | Biocompatible long-fiber nonwoven fabric, production method therefor, three-dimensional scaffold for cell culturing, and cell culturing method using same |
JP7038368B2 (en) * | 2019-11-21 | 2022-03-18 | 日本毛織株式会社 | Cell aggregate, its production method, its preparation kit, and method for evaluating compounds using it. |
Also Published As
Publication number | Publication date |
---|---|
JP7267172B2 (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6450894B1 (en) | Biocompatible long-fiber nonwoven fabric, production method thereof, solid scaffold for cell culture, and cell culture method using the same | |
EP1835949B1 (en) | Tissue engineering devices for the repair and regeneration of tissue | |
KR101027630B1 (en) | Preparation method of porous scaffold by hyaluronic acid - collagen natural polymer for cartilage resuscitation | |
US9402710B2 (en) | Macroporous 3-D scaffolds for tissue engineering | |
US20060153815A1 (en) | Tissue engineering devices for the repair and regeneration of tissue | |
Skotak et al. | Improved cellular infiltration into nanofibrous electrospun cross-linked gelatin scaffolds templated with micrometer-sized polyethylene glycol fibers | |
Lin et al. | In vitro and in vivo evaluation of the developed PLGA/HAp/Zein scaffolds for bone-cartilage interface regeneration | |
KR100846311B1 (en) | Porous collagen-hyaluronic acid complex material and method for the preparation thereof | |
CN102277737A (en) | Preparation method and application of polycaprolactone/natural high-molecular composite porous scaffold | |
US10369252B2 (en) | Electrospun three-dimensional nanofibrous scaffolds with interconnected and hierarchically structured pores | |
JP7038368B2 (en) | Cell aggregate, its production method, its preparation kit, and method for evaluating compounds using it. | |
WO2020262469A1 (en) | Gelatin short fiber, production method thereof, cell aggregates including same, production method of cell aggregates, and production kit | |
JP5320526B1 (en) | Method for producing auricular cartilage tissue and auricular cartilage tissue | |
JP7267172B2 (en) | Three-dimensional scaffold for cell culture, method for producing the same, method for seeding cells using the same, and method for cell culture | |
JP7362652B2 (en) | Cell sheet, its manufacturing method and production kit | |
Wasyłeczko et al. | Three-dimensional scaffolds for bioengineering of cartilage tissue | |
De Coppi | Tissue engineering and stem cell research | |
WO2022138206A1 (en) | Wound dressing material | |
JP2002291461A (en) | Method for culturing chondrocyte and substrate for regenerating cartilaginous tissue | |
JP4393888B2 (en) | Scaffolding material | |
He et al. | Decellularized Fibrin Gel-Covered Canine Carotid Artery: A Completely Biological Composite Scaffold for Tissue-Engineered Small-Caliber Vascular Graft | |
EP3034102A1 (en) | Stem cell carrier and method for bone regeneration with 3D customized CAD/CAM using the carrier | |
JP2022055039A (en) | Cell transplant material, manufacturing method thereof, and method of use thereof | |
Cecen et al. | Two layered scaffolds (Loofah/PLLA/cellulose/chitin) for repair of osteochondral defect | |
JP2023131487A (en) | Sustained-release base material, method for producing the same, and sustained-release material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220131 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7267172 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |